Bordeaux

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Childhood cancers1 trial
• Head and neck cancer1 trial
• HIV1 trial
• Sarcoma1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 23 trials
• Phase 32 trials
• Phase 11 trial
• Phase 1/21 trial

Status

• Active, not recruiting4 trials
• Completed2 trials
• Recruiting1 trial

Lead sponsor

• GlaxoSmithKline5 trials
• Tesaro, Inc.1 trial
• ViiV Healthcare1 trial

Running trials

• Recruiting

  A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

  NCT07602777· Phase 1/2· GlaxoSmithKline· Source

  Contact: Maud Toulmonde (principal investigator)

• Active, not recruiting

  A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

  NCT06062420· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

  NCT04915755· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

  NCT02715284· Phase 1· Tesaro, Inc.· Source

• Active, not recruiting

  Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

  NCT02362503· Phase 3· ViiV Healthcare· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers1 recruiting
• Sarcoma1 recruiting

Closed trials

• Completed

  Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

  NCT06926673· Phase 2· GlaxoSmithKline· Source

• Completed

  Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

  NCT03739710· Phase 2· GlaxoSmithKline· Source